⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 1, 2002British Journal of Clinical PharmacologyOpen Access

Sex and age differences in the pharmacokinetics of alosetron

Kevin M. Koch Jonathan Palmer N. Noordin Julie J. Tomlinson Charlotte A. Baidoo

View Full Paper

Ask AI

Bookmark

Share

Abstract

A significant difference in clearance by metabolism of alosetron between the sexes, and possibly between the young and elderly was observed.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Koch et al. (2002) studied this question.

synapsesocial.com/papers/69dc443a4f901957bec0ff57 https://doi.org/10.1046/j.0306-5251.2001.01565.x

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT<sub>3</sub> receptor antagonistRCT · 1999 · 369 citations
2Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.Original Research · 1989 · 345 citations
3The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin*Original Research · 1998 · 411 citations
4A Study of the Effect of Age and Gender on the Pharmacokinetics of Nefazodone After Single and Multiple DosesOriginal Research · 1996 · 54 citations
5Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2* activitiesOriginal Research · 1992 · 314 citations

More related papers

Influence of patient-related variables on clozapine plasma levels1990
Effects of age and sex on piroxicam disposition1985
Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites1992

More from British Journal of Clinical Pharmacology

Interpreting ‘similar outcomes’ in a small real‐world comparison of apixaban and vitamin K antagonistsTue,
Desethylhydroxychloroquine and CYP2D6 polymorphisms are associated with low disease activity in patients with systemic lupus erythematosusFri,